Opioid bowel dysfunction and narcotic bowel syndrome: A population-based study

American Journal of Gastroenterology

Volumn 104, Issue 5, 2009, Pages 1199-1204

  Choung, Rok Seon ^a   Locke, G Richard ^a   Zinsmeister, Alan R ^a   Schleck, Cathy D ^a   Talley, Nicholas J ^a,b  

^a MAYO CLINIC   (United States)

^b Department of Internal Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAXATIVE; NARCOTIC AGENT; OPIATE; NARCOTIC ANALGESIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHRONIC PAIN; COMMUNITY ASSESSMENT; DISEASE ASSOCIATION; DRUG USE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NARCOTIC BOWEL SYNDROME; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; AGE DISTRIBUTION; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HOSPITALIZATION; INCIDENCE; MIDDLE AGED; OPIATE ADDICTION; PATHOLOGY; PROBABILITY; PROGNOSIS; REFERENCE VALUE; RISK ASSESSMENT; SEX RATIO; STATISTICAL MODEL; SYNDROME;

ABDOMINAL PAIN; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHRONIC DISEASE; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; NARCOTICS; OPIOID-RELATED DISORDERS; PROBABILITY; PROGNOSIS; QUESTIONNAIRES; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SYNDROME;

EID: 66949173732     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.71     Document Type: Article

References (32)

1. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63:649-71.
2. Quality improvement guidelines for the treatment of acute pain and cancer pain. American Pain Society Quality of Care Committee. JAMA 1995;274: 1874-80.
3. Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dysfunction. Dig Dis 2006;24:105-12.
4. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182:11S-8S.
5. Friedman JD, Dello Buono FA. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacother 2001;35:85-91.
6. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61:1181-7.
7. Grond S, Zech D, Diefenbach C et al. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1,635 cancer patients referred to a pain clinic. J Pain Symptom Manage 1994;9:372-82.
8. Sandgren JE, McPhee MS, Greenberger NJ. Narcotic bowel syndrome treated with clonidine. Resolution of abdominal pain and intestinal pseudo-obstruction. Ann Intern Med 1984;101:331-4.
9. Rogers M, Cerda JJ. The narcotic bowel syndrome. J Clin Gastroenterol 1989:11:132-5.
10. IMS. Health National Prescription Audit, 2006.
11. Sandoval JA, Furlan AD, Mailis-Gagnon A. Oral methadone for chronic noncancer pain: a systematic literature review of reasons for administration, prescription patterns, effectiveness, and side effects. Clin J Pain 2005:21:503-12.
12. Watkins A, Wasmann S, Dodson L et al. An evaluation of the care provided to patients prescribed controlled substances for chronic nonmalignant pain at an academic family medicine center. Fam Med 2004;36:487-9.
13. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996:71:266-74.
14. Melton LJ III. The threat to medical-records research. N Engl J Med 1997;337:1466-70.
15. Talley NJ, Zinsmeister AR, Melton LJ III. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995:142:76-83.
16. Talley NJ, Zinsmeister AR, Van Dyke C et al. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991;101:927-34.
17. Talley NJ, Phillips SF, Melton J III et al. A patient questionnaire to identify bowel disease. Ann Intern Med 1989;111:671-4.
18. O'Keefe EA, Talley NJ, Tangalos EG et al. A bowel symptom questionnaire for the elderly. J Gerontol 1992;47:M116-21.
19. Castillo EJ, Camilleri M, Locke GR et al. A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol 2004;2:985-96.
20. Grunkemeier DM, Cassara JE, Dalton CB et al. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007;5:1126-39; quiz 1121-2.
21. Attanasio V, Andrasik F, Blanchard EB et al. Psychometric properties of the SUNYA revision of the psychosomatic symptom checklist. J Behav Med 1984;7:247-57.
22. Locke GR III, Zinsmeister AR, Talley NJ et al. Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol 2000;95:157-65.
23. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987:40:373-83.
24. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992:45:613-9.
25. Pletcher MJ, Kertesz SG, Kohn MA et al. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA 2008:299:70-8.
26. Wong V, Sobala G, Losowsky M. A case of narcotic bowel syndrome successfully treated with clonidine. Postgrad Med J 1994:70:138-40.
27. Clouse RE, Mayer EA, Aziz Q et al. Functional abdominal pain syndrome. Gastroenterology 2006:130:1492-7.
28. Meuser T, Pietruck C, Radbruch L et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001:93:247-57.
29. Kalso E, Edwards JE, Moore RA et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372-80.
30. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005;7:R1046-51.
31. Campora E, Merlini L, Pace M et al. The incidence of narcotic-induced emesis. J Pain Symptom Manage 1991:6:428-30.
32. Aparasu R, McCoy RA, Weber C et al. Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. J Pain Symptom Manage 1999:18:280-8.